Proshares Ultra Nasdaq Biotech

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

Gilead's Yeztugo Revenues Surged 73% QoQ, Exceeding Market Expectations

Daiwa Securities Downgrades Amgen's Target Price to $390.00

WHO Procurement Mechanism Selects South African Lab to Produce AIDS Generic Drug

Amgen Advances Obesity Drug MariTide to Phase III Trial

Analysts at Cantor Fitzgerald and Bernstein Give Buy Rating to Gilead Sciences

Gilead Sciences released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 6.96 B (forecast USD 6.929 B), actual EPS USD 1.61 (forecast USD 1.5805)

Gilead Sciences Raises 2026 Sales Forecast

Gilead Sciences reports Q1 product sales of $6.946 billion

WealthShield Partners LLC builds new position and increases holdings in Gilead Sciences

Amgen Invests in Expanding Its Research Center to Accelerate Drug Development

Vertex Pharmaceuticals Reports Q1 Revenue Below Expectations, EPS Above Expectations

Goldman Sachs Analyst Reiterates Buy Rating on Regeneron Pharmaceuticals

Regeneron Announces Positive Results for Dupixent in EoE Trial

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

Barclays Remains a Buy on Bayer (0P6S)

BAYRY

SBIO

LABU

Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rating with an average return of 11.4%. UBS also rated Bayer as a Buy, while Deutsche Bank issued a Hold rating on the same day.

Tip Ranks

Bayer

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

iShares Global Healthcare

iShares US Pharma

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Barclays

Bayer Aktiengesellschaft

UBS Group AG

Deutsche Bank AG

Bayer AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

ORKA

IBBQ

ARKG

Oruka Therapeutics SVP Arjun Agarwal sold 10,290 shares at $59.07 each, totaling $607,830.30, representing a 38.55% decrease in his ownership. Post-sale, he holds 16,406 shares valued at $969,102.42. The transaction was made under a Rule 10b5-1 plan and disclosed to the SEC. The stock is currently trading down 5.8% at $58.34.

Market Beat

Oruka Therapeutics

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

ROYAL BANK OF CANADA

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock

SBFMW

SBFM

Sunshine Biopharma Inc. has priced a $6 million public offering, consisting of 12 million common units at $0.50 each, sending shares up 79.51% to $0.51. The offering includes Series C warrants exercisable at $0.50 for five years. Proceeds will support corporate purposes and working capital. The company markets 60 generic drugs in Canada and plans to launch 12 more in 2026, while advancing proprietary programs targeting oncology and SARS-related coronaviruses.

nasdaq

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

VG Health

Nasdaq

Sunshine Biopharma Prices $6M Offering; Closing May 19

BMRN

BioMarin’s BMN 401 raised plasma PPi over 52 weeks in children but showed no meaningful rickets or growth improvement. Shares fell about 3% to ~$50.10 after the announcement.12HC Wainwright & Co. reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (BMRN) and lowered its price target for the stock from $55.00 to $50.00 per share.3

TradingView

BioMarin Pharma

Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50

VRAX

Virax Biolabs (VRAX) shares surged 17.36% to $0.28 in after-hours trading, following a 53.09% intraday gain. Armistice Capital disclosed a 4.99% stake in VRAX. The company is advancing ViraxImmune, targeting post-acute infection syndromes. Despite a market cap of $4.79 million, VRAX's stock has dropped 78.04% over the past year, trading closer to its 52-week low of $0.10.

fidelity

Bakkt

BAKKT INC C/WTS 25/10/2026 (TO PUR COM)

Why Is Virax Biolabs (VRAX) Stock Trending Overnight?

RVPH

OTC Markets Group has approved Reviva Pharmaceuticals, along with Uraniumx Discovery and zSpace, to begin trading on its OTCQB Venture Market starting May 18.

PUBT

Reviva Pharmaceuticals

Zspace

Reviva Pharmaceuticals - CW23

OTC Markets approves Reviva Pharmaceuticals for trading on OTCQB Venture Market

ATYR

RBC Capital has maintained a Hold rating on aTyr Pharma (ATYR) with a price target of $1.00, while the shares closed at $0.50. Analyst Brian Abrahams has an average return of 10.7% and a 52.10% success rate. Wells Fargo also issued a Hold rating, while Piper Sandler maintained a Buy rating on May 12.

ATYR Pharma

Gilead Sciences

Regeneron Pharma

Biogen

Wells Fargo

Piper Sandler Cos

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)

LLYX

The company is riding an incredible tailwind.

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Eli Lilly stock: Next stop $2,000?

NTHI

NeOnc Technologies Holdings, Inc. reported progress in its glioma programs, completing a Phase 1 study of NEO212 and enrolling in a Phase 2a trial of NEO100. The company improved its financial position with a $10 million PIPE financing and reduced its quarterly net loss to $8.8 million. Analysts rate NTHI stock as a Buy with a $20.00 target, though concerns about financial performance persist. NeOnc focuses on CNS cancers, developing drugs under FDA Fast-Track status.

Neonc Tech

NeOnc Advances Glioma Programs and Strengthens Financial Position

REGN

Levi & Korsinsky is investigating Regeneron Pharmaceuticals (REGN) following significant stock losses after the failure of its Phase 3 melanoma trial of fianlimab + Libtayo. The stock dropped over 10% after the trial did not meet its primary endpoint. Shareholders who suffered losses are encouraged to contact the firm for potential legal recourse.

prnewswire

Direxion S&P Biotech Bear 3X

18:24 ETRegeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)

Health-care companies saw gains as traders shifted focus to underperforming sectors. However, Regeneron Pharmaceuticals experienced a significant drop in shares following a failed late-stage study of its fianlimab drug for melanoma. Additionally, an American contracted Ebola in the Democratic Republic of Congo amid an ongoing outbreak.

MorningStar

Health Care Up on Rotation Into Lagging Sectors — Health Care Roundup

Proshares Ultra Nasdaq Biotech(BIB.US)

Barclays Remains a Buy on Bayer (0P6S)

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock

Sunshine Biopharma Prices $6M Offering; Closing May 19

Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50

Why Is Virax Biolabs (VRAX) Stock Trending Overnight?